Abstract
Ten patients with plaque-type psoriasis were treated with 2 mg peptide T i.v. for 28 days. Six patients responded with a substantial clinical improvement. Sequential biopsies from skin lesions were taken before, during and after treatment. The histological score (defining the activity of the psoriasis), the epidermal thickness and the number of infiltrating dermal lymphocytes were all reduced in the six patients who responded to the treatment. An increase in the number of CD1+ dendritic cells was detected immunohistochemically in the epidermis of the responders. The nonresponders did not display any pronounced changes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pert C (1989) The development of peptides and the promise of peptide T as a therapy for AIDS. Mod Med 57: 44–53
Lachmann P, Peters K, Rosen F, Walport M (1993) Clinical aspects of immunology. In: Calvelli TA, Sicklick MJ, Rubinstein A (eds) Paediatric acquired immune deficiency syndrome, vol 70. Blackwell Scientific, pp 1341–1368
Brenneman D, Buzy J, Ruff M, Pert C (1988) Peptide T sequences prevent neuronal cell death produced by the envelope protein (Gp 120) of the human immunodeficiency virus. Drug Dev Res 15: 361–369
Buzy J, Brenneman D, Pert C, Martin A, Salazar A, Ruff M (1992) Potent Gp 120-like neurotoxic activity in the cerebrospinal fluid of HIV-infected individuals is blocked by peptide T. Brain Res 598: 10–18
Ruff M, Martin B, Ginns E, Farrar W, Pert C (1987) CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. FEBS Lett 211: 17–22
Moore T, Spruck C, Said S (1988) In vivo depression of lymphocyte traffic in sheep by VIP and HIV (AIDS)-related peptides. Immunopharmacol 16: 181–189
Wetterberg L, Alexius B, Sääf V, Söönerborg A, Britton S, Pert C (1987) Peptide T in treatment of AIDS. Lancet II: 159
Marcusson J, Wetterberg L (1989) Peptide T in the treatment of psoriasis and psoriatic arthritis. Acta Derm Venereol (Stockh) 69: 86–88
Marcusson J, Lazega D, Pert C, Ruff M, Sundquist K-G, Wetterberg L (1989) Peptide T and psoriasis. Acta Derm Venereol Suppl (Stockh) 146: 117–121
Marcusson J, Talme T, Wetterberg L, Johansson O (1991) Peptide T — a new treatment for psoriasis? Acta Derm Venereol (Stockh) 71: 479–483
Fredriksson T, Pettersson U (1978) Severe psoriasis — oral therapy with a new retinoid. Dermatologica 157: 238–244
Farber E, Cohen E, Trozak D, Wilkinson D (1991) Peptide T improves psoriasis when infused into lesions in nanogram amounts. J Am Acad Dermatol 25: 658–664
Haftek M, Faure M, Schmitt D, Thivolet J (1983) Langerhans cells from patients with psoriasis: quantitative and qualitative study of T6 and HLA-DR antigen-expressing cells and changes with aromatic retinoid administration. J Invest Dermatol 81: 10–14
Lisi P (1973) Investigation on Langerhans cells in pathological human epidermis. Acta Derm Venereol (Stockh) 53: 425–428
Bieber T, Braun-Falco O (1989) Distribution of CD 1a-positive cells in psoriatic skin during the evolution of the lesions. Acta Derm Venereol (Stockh) 69: 175–178
Baker B, Swain A, Fry L, Valdimarsson H (1984) Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 110: 555–564
Baker B, Swain A, Griffiths C, Leonard J, Fry L, Valdimarsson H (1985) Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. Clin Exp Immunol 61: 526–534
Baker B, Swain A, Griffiths C, Leonard J, Fry L, Valdimarsson H (1985) The effects of topical treatment with steroids or dithranol on epidermal T lymphocytes and dendritic cells in psoriasis. Scand J Immunol 22: 471–477
Baker B, Griffiths C, Lambert S, Powles A, Leonard J, Valdimarsson H, Fry L (1987) The effects of cyclosporine A on T lymphocyte and dendritic sub-populations in psoriasis. Br J Dermatol 116: 503–510
Horrocs C, Duncan J, Sewell H, Ormerod A, Thomson A (1990) Differential effects of cyclosporine A on Langerhans cells and regulatory T-cell populations in severe psoriasis: an immunohistochemical and flow cytometric analysis. J Autoimmun 3: 559–570
Morel P, Revillard J-P, Nicolas J-F, Wijdenes J, Rizova H, Thivolet J (1992) Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmun 5: 465–477
Heng M, Allen S, Haberfelde G, Song M (1991) Electron microscopic and immunocytochemical studies of the sequence of events in psoriatic plaque formation following tape-stripping. Br J Dermatol 125: 548–556
Griffiths C, Voorhees J, Nickoloff B (1989) Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 20: 617–629
Nathan CF, Kaplan G, Lewis WR (1986) Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 315: 6–11
Terui T, Aiba S, Kato T, Tanaka T, Tagami H (1987) HLA-DR antigen expression on keratinocytes in highly inflamed parts of psoriatic lesions. Br J Dermatol 116: 87–93
Gottlieb A, Lifshitz B, Fu S, Staiano-Coico L, Wang C, Carter M (1986) Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in dermal infiltrate of active psoriatic plaques. J Exp Med 164: 1013–1028
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Talme, T., Marcusson, J.A., Rozell, B.L. et al. Histopathological and immunohistochemical changes in psoriatic skin during peptide T treatment. Arch Dermatol Res 287, 553–557 (1995). https://doi.org/10.1007/BF00374075
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00374075